Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II adaptive open-label study of BNT326 alone and in combination with BNT327 in advanced solid tumors
CTR20262342Phase 2Active
- Sponsor
- BioNTech
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202 in Nonhematologic neoplasms, sponsored by BioNTech. Started Aug 2025; status: active.
02
Drugs
YL202
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20262342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262342.